Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance

Abbott’s second-quarter 2026 update showed continued growth and prompted guidance changes as the company reports sales momentum and earnings performance. Second-quarter reported sales grew 13.0%, while comparable sales rose 4.8%. Abbott posted GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31 for the quarter. The company reaffirmed its full-year 2026 comparable sales growth outlook of 6.5% to 7.5%, maintaining the same range it previously set. In parallel, Abbott raised full-year 2026 adjusted EPS guidance, signaling stronger profitability expectations for the remainder of the year. The announcement matters to investors tracking Abbott’s execution versus peers in the healthcare products sector.